Week in Review: Jiangsu Aosaikang Pharma Delays China IPO

Jiangsu Aosaikang Pharma temporarily delayed its $669 million China IPO, saying it was “relatively large,” which didn’t exactly explain the holdup; Changchun High & New Technology Industries paid $4.8 million for a 25% interest in Dutch vaccine maker Mucosis; Wuhan Kindstar Clinical Diagnostics in-licensed a lung cancer test from Germany’s Epigenomics; Thermo Fisher was OK’d by China for its $13.6 billion acquisition of Life Technologies; TaiGen Biotech of Taiwan and Beijing out-licensed Russian rights for its novel antibiotic to R-Pharm of Russia; China issued additional regulations for conducting IPOs under its new “market-oriented” system; Actavis will quit China because it considers the business environment too difficult and the potential profits too small; GlaxoSmithKline said its China revenues turned higher in the fourth quarter of 2013 after dropping a disastrous 61% in Q3; US-based Neuralstem treated its first patient in a China stem cell trial of a stroke treatment; and EntreMed filed a clinical trial application for a China Phase II trial of its ovarian cancer treatment. More details…. Stock Symbols: (SHE: 300361) (F: ECX, OTC: EPGNY) (NYSE: TMO) (NSDQ: LIFE) (NYSE: ACT) (NYSE: GSK) (NYSE: CUR) (NSDQ: ENMD) Share this with colleagues: // //